F-star

F-star Therapeutics has transitioned to an independent entity, reclaiming its narrative after separating from former acquirer invoX Pharma. The U.K.-based company is focused on advancing its innovative bispecific antibody platform,…

F-star Therapeutics is emerging as an independent biotech company following its $161 million acquisition by invoX Pharma, a subsidiary of Sino Biopharmaceutical. The acquisition faced regulatory challenges, particularly with the…